65,437 trials
Arthroplasty, Replacement, Hip · Blood Transfusion · Blood Transfusion, Autologous
Primary: Number of Participants in Need for Bank Blood Transfusion — 9; 13 Participants
Asthma
Primary: Percentage of Asthma-control Days Over the 6-month Treatment Period — 50.70; 53.30; 43.84 Percentage of days
Dry Eye Syndromes
Primary: Tear Osmolarity in Human Measured by TearLab System — 308 mOsms/L
Spinal Muscular Atrophy
Primary: Safety Labs
Rheumatoid Arthritis
Primary: Double Blind Period (DB); Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuation, Adverse Events (AEs), Related…
Epilepsy · Sleep Apnea · Obstructive Sleep Apnea
Primary: CPAP Adherence/Tolerance as Measured by Proportion of Nights Used — 0.74; 0.66 proportion of nights used (total nights — p=0.26
Stage 2 Hypertension
Primary: Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 8 — 164.8; 166.2; 142.3; 145.6 mm Hg — p=0.295
Transfusional Iron Overload in β-thalassemia
Primary: Long Term Safety and Tolerability Profile of ICL670 Based on the Number of Participants Who Experienced Any Adverse Event — 109; 113; 85; 110 Participants
Kidney Diseases
Primary: Renal Function Assessed by Change in Estimated Glomerular Filtration Rate(eGFR) — 45.3; 56.4; 44.7; 49.1 mL/min/1.73m^2
Macular Degeneration · Choroidal Neovascularization
Primary: Percentage of Participants Who Lose Less Than 15 Letters of Best Corrected Visual Acuity (BCVA) at 12 Months From Baseline. — 59.4; 63.4; 71.1 Percentage of Participants
Sternal Wound Infection · Mediastinitis
Primary: Percentage Change of Preoperative Incentive Spirometry (IS) Volume Achieved — 58; 67 percentage change — p=0.41
Skin Manifestations
Primary: Number of Participants Who Were a Success With Regard to Worst Post-baseline Tolerability Assessment Scores in Each Category of the Tolerability Assessments (Erythema…
Sickle Cell Disease · Iron Overload · Hemolytic Anemia
Primary: The Number of Participants With Adverse Events (AEs) in the First 24 Weeks of Treatment — 30; 17; 30; 8 participants
Infections, Papillomavirus
Primary: Anti-Human Papillomavirus (Anti-HPV)-16/18 Antibody Titers in Serum at Years 5, 6 and 7 — 1495.7; 518.7; 282.4; 1344.6 EL.U/mL
Thalassemia · Sickle Cell Disease · Diamond Blackfan Anemia
Primary: Safety Profile of Deferasirox Based Upon Drug Administration and Reporting of Serious Adverse Events — 0; 0; 1; 4 Participants